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Abstract
Kynurenine aminotransferases are key enzymes for the synthesis of kynurenic acid (KYNA), an endogenous glutamate receptor
antagonist. The study described here examined ontogenic changes of kynurenine aminotransferase I (KAT I) activity and its ex-
pression in the chicken retina. KAT I activity measured on embryonic day 16 (E16) was signiﬁcantly higher than at all other stages
(E12, P0 and P7). Double labeling with antibodies against glutamine synthetase showed that on P7 KAT I was expressed in M€uller
cell endfeet and their processes in the inner retina. Since KAT I activity is high in the late embryonic stages, it is conceivable that it
plays a neuromodulatory role in the retina during the late phase of embryogenesis.
 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The tryptophan metabolite kynurenic acid (KYNA)
is the only known naturally occurring endogenous
glutamate receptor antagonist in the brain (Perkins &
Stone, 1982). KYNA in low micromolar concentrations
antagonises the glycine site of the NMDA receptor
complex (Kessler, Terramani, Lynch, & Baudry, 1989).
There is also evidence that KYNA may be a potent
noncompetitive antagonist of acetylcholine a7 nicotinic
receptors (Hilmas et al., 2001).
It has been suggested that KYNA modulates gluta-
mate-mediated synaptogenesis and neurotransmission
during brain development (Ceresoli-Borroni & Schw-
arcz, 2001). Importantly, changes of KYNA content
have been observed in both rat and chicken retinas
during ontogeny (Rejdak et al., 2002).
In mammalian cells, KYNA is synthesized by irre-
versible transamination of L-kynurenine by two distinct
kynurenine aminotransferases, KAT I and II (Guidetti,
Okuno, & Schwarcz, 1997). KYNA is cleared from the
brain almost as quickly as it is formed (Moroni, Russi,
Lombardi, Beni, & Carla, 1988; Turski et al., 1988), and
only 10% of newly synthesized KYNA is retained in
neural tissues; the rest is liberated into the extracellular
space (Turski, Gramsbergen, Traitler, & Schwarcz,
1989) where it becomes active and is cleared into the
blood stream (Speciale et al., 1990; Turski & Schwarcz,
1988) KATs are highly suitable candidates for bio-
chemical and immunohistochemical investigations (Ka-
poor, Okuno, Kido, & Kapoor, 1997). KAT I is a
soluble enzyme and prefers pyruvate as a co-substrate
(Okuno et al., 1990). It has been demonstrated immu-
nohistochemically in the rat brain (Du et al., 1992;
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Knyihar-Csillik, Okuno, & Vecsei, 1999; Roberts, Du,
McCarthy, Okuno, & Schwarcz, 1992), the medulla, and
the spinal cord (Kapoor et al., 1997). KAT II was ﬁrst
identiﬁed by Northern blot mRNA analysis in the
human brain (Okuno, Nakamura, & Schwarcz, 1991).
Only recently, we showed that both KAT I and II were
present in the inner retina of the adult rat (Rejdak et al.,
2001).
Biochemical analysis of tissue homogenates has
shown that enzymatic activity of both KAT I and II is
present throughout the brain (Okuno et al., 1991) as well
as in the endothelium of vessels (Stazka, Luchowski,
Wielosz, Kleinrok, & Urbanska, 2002).
Since avian retinas are avascular (Wolburg, Liebner,
Reichenbach, & Gerhardt, 1999), any contamination of
retinal samples with KYNA-producing enzymes in such
retinas from retinal vessels can be excluded. This makes
it possible to examine and qualify the course of KAT I
activity during avian retinal development independently
of progressive vascularisation.
The present study examined developmental changes
of KAT I enzymatic activity and its cellular expression
in the chicken retina.
2. Material and methods
All experiments were performed in compliance with
the guidelines of animal care in the European Commu-
nity and the Association for Research in Vision and
Ophthalmology.
2.1. Animals
Fertilised White Leghorn eggs and male chickens
were supplied by a local hatchery. For tissue prepara-
tion, the chickens were deeply anaesthetised with ether
between embryonic day 12 (E12) and postnatal day 21
(P21) and decapitated, and the eyes were immediately
enucleated. Following hemisection of an eye along the
ora serrata the cornea, lens, vitreous body and pecten
were removed and the whole neural retinas were then
dissected free from the retinal pigment epithelium,
choroid and sclera. To assay KAT I activity, retinas
were immediately frozen in liquid nitrogen after removal
or embedded in cryomatrix for immunohistochemistry.
2.2. Determination of KAT I activity
KAT I activity was assayed according to the method
of Guidetti et al. (1997), with modiﬁcations. Tissue was
homogenized (1:10; w=v) in 5 mM Tris–acetate buﬀer,
pH 8.0, containing 50 lM pyridoxal-phosphate and 10
mM 2-mercaptoethanol. The resulting homogenate was
dialyzed overnight at 8 C using cellulose membrane
dialysis tubing against 4 l of the same buﬀer. Active
samples contained the enzyme preparation with a reac-
tion mixture containing 2 mM L-kynurenine, 1 mM
pyruvate, 70 lM pyridoxal-50-phosphate, 150 mM Tris–
acetate buﬀer pH 9.5 (KAT I), in a total volume of 0.2
ml. Blanks containing heat-deactivated enzyme (100 C
for 10 min) and active samples were incubated at 37 C
for 24 h. The reaction was terminated by immediate
transfer of the samples to an ice-bath and the addition of
10 ll of 50% trichloroacetic acid. The denaturated
proteins were removed by centrifugation, and the
supernatant was applied to the columns containing ca-
tion-exchange resin (Dowex 50 Wþ: 200–400 mesh)
prewashed with 0.1 M HCl. Subsequently, the columns
were washed with 1 ml of 0.1 M HCl and 1 ml of water,
and the fraction containing KYNA was eluted with 2 ml
of water. Eluate was subjected to HPLC, and KYNA
was detected ﬂuorometrically (Hewlet Packard 1050
HLC system: ESA catecholamine HR-80, 3 lm, C18
reverse-phase column, ﬂow rate of 1.0 ml/min; Hewlet
Packard 1046A ﬂuorescence detector: excitation 344 nm,
emission 398 nm). L-kynurenine (sulphate salt), KYNA,
glutamine, pyruvate, pyridoxal-50-phosphate, 2-merca-
ptoethanol and cellulose membrane dialysis tubing were
obtained from Sigma (St. Louis, USA). All HPLC re-
agents were obtained from Baker (Holland).
Statistical analysis was performed using one-way
analysis of variance (ANOVA) followed by Student–
Newman–Keuls post hoc test. A p-value of less than
0.05 was considered signiﬁcant.
2.3. Immunohistochemistry
Embedded retinas were radially sliced in 10 lm thick
sections, and the sections were mounted on gelatin-
coated glass slides. All immunohistochemical incubation
steps were carried out on these slides. Endogenous
peroxidase was blocked with 3% H2O2 in 40% methanol;
subsequently, sections were incubated for 1 h with 10%
normal goat serum (NGS; Sigma, Munich, Germany)
and 0.3 % Triton X-100 in phosphate-buﬀered saline
(PBST) to reduce background staining. The primary
antibodies were diluted in PBST containing 10% NGS
for immunohistochemistry with antibodies against KAT
I and incubated overnight at 4 C. KAT I was detected
using an anti-KAT I polyclonal antibody raised in
rabbit against rat kidney KAT (Okuno et al., 1990). A
monoclonal antibody directed against glutamine syn-
thetase was used as a marker for M€uller cells (Chem-
icon, dilution 1:500).
Antibodies were diluted 1:50 in PBST. After washing
with PBS, the samples were incubated for 1 hour with
the biotin-conjugated secondary antibody (dilution
1:200; Vectastain Elite Kit; Vector Laboratories, Bur-
lingame, CA) in PBST with 5% NGS. After rinsing in
PBS, retinal sections were processed with an avidin–
biotin–peroxidase complex (Vectastain Elite Kit; Vector
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Laboratories), and staining was visualized with diam-
inobenzidine reaction products. For double-labeling
immunoﬂuorescence, the preblocking step and primary
antibody incubation were performed in 20% NGS plus
2% bovine serum albumin (BSA, Sigma). The secondary
antibodies were conjugated either to Alexa 568 rabbit,
and Alexa 488 mouse (bought from Molecular Probes;
dilutions were 1:1000).
3. Results
3.1. KAT I activity
KAT I activity in 12-day-old (E12) and 16-day-old
(E16) embryonic retinas was 0.88 0.1 ðn ¼ 4Þ and
2.1 0.27 ðn ¼ 4Þ (pmol/mg protein, mean SE) re-
spectively. At P0 it reached a concentration of 1.1 0.35
ðn ¼ 5Þ and stayed at a comparable level (1.06 0.2,
n ¼ 5) at P7. The KAT I activity in E16 was signiﬁcantly
higher ðp ¼ 0:043Þ than at other stages (Fig. 1).
Chromatograms showed a peak identical to that ob-
tained for commercially available KYNA (data not
shown).
3.2. Immunohistochemistry
KAT I immunoreactivity was concentrated in the
inner retina. The most prominent staining was found
below the cell bodies of the ganglion cell layer up to the
retina-vitreous border. In addition, labeling was present
in processes ascending from this brightly stained band
into the inner plexiform layer (IPL) and up to innermost
row of the inner nuclear layer (INL) (Fig. 2(A)).
Double labeling with KAT I antibody (Fig. 2(A)) and
glutamine synthetase antibody (Fig. 2(B)) revealed a
clear co-expression of both antibodies. Double labeling
was especially prominent in the endfeet of M€uller cells
and in the processes surrounding the cell bodies in the
ganglion cell layer (GCL). It was also found, although
less distinctly, along the distal margin of the KAT I
immunoreactivity in the INL (Fig. 2(C)).
4. Discussion
The experiments in the present study demonstrated
that KAT I activity is already present in the chicken
retina at early stages of ontogeny. KAT I activity
measured at E16 was higher by 58% than at E12 and
higher by 48% than at P0. KAT I activity measured at P
7 was more or less at the same level as at P0. Since it has
been proven that KAT I activity contributes to the
formation of KYNA (Guidetti et al., 1997), these data
correspond to our previous ﬁndings showing that in the
chicken retina KYNA concentrations were signiﬁcantly
higher at E16 than at E12 and rapidly decreased to adult
levels by postnatal day 7. In the rat retina KYNA
content peaked at birth, when it was 7 times higher then
at E20 and then decreased during the ﬁrst two weeks of
life (Rejdak et al., 2002).
It has been suggested that changes of KYNA avail-
ability might modulate the function of excitatory syn-
apses (Carpenedo et al., 2001). In the immature brain,
NMDA receptors are crucial for the modulation of
neuronal migration (Komuro & Rakic, 1993) and for
synapse development (Schwarcz, Poeggeler, Rassoul-
pour, Ceresoli-Borroni, & Hodgkins, 1998). Since
glutamate receptors are already present at birth and
show diﬀerences in spatial distribution and temporal
expression in both chicken (Somohano, Roberts, &
Lopez-Colome, 1988) and rat retinas (Grunder, Kohler,
& Guenther, 2000; Grunder, Kohler, Kaletta, & Guen-
ther, 2000), it is possible that marked changes of KAT I
activity in the pre- and post-hatching period, such as
those observed in the present study, lead to the previ-
ously reported changes of retinal KYNA metabolism
(Rejdak et al., 2002) and modulate glutamate-mediated
synaptogenesis and neurotransmission in the retina.
Since it has been suggested that KAT I plays a role in
the regulation of programmed cell death (Csillik, Ok-
uno, Csillik, Knyihar, & Vecsei, 2002) it is conceivable
that KAT I and KYNA may control apoptosis in the
retina during early development.
Glutamate has been shown to diminish KYNA syn-
thesis in brain slices, and its regulatory inﬂuence on
endogenous KAT activity has been suggested (Urban-
ska, Chmielewski, Kocki, & Turski, 2000). An increase
in retinal glutamate content occurs as glutamatergic cells
mature in other species (Haberecht & Redburn, 1996)
and it is possible that the decrease in retinal KAT I
activity might result from a similar changes in glutamate
level in chick retinas.
Kynurenate formation is controlled by the avail-
ability of L-kynurenine (Turski et al., 1989) and the
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Fig. 1. KAT I activity at diﬀerent developmental stages (E12–P7) of
the chicken retina. Each column represents the mean SE (pmol/mg
protein). KAT I activity at E16 is signiﬁcantly higher ðp < 0:05Þ than
at all other stages.
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activities of KAT (Guidetti et al., 1997). Interestingly,
studies on age-related changes of KAT activity in the rat
brain showed a marked heterogeneity of enzymatic
changes between brain regions. A signiﬁcant increase of
KYNA production in the cortex, the hippocampus and
the striatum during ageing was observed, while in the
thalamus and the cerebellum changes were much less
pronounced in adult rats and a decrease was even found
in older animals (Gramsbergen, Schmidt, Turski, &
Schwarcz, 1992). Taking into consideration the results
of the present study, it is conceivable that age-related
changes of KYNA synthesis are speciﬁc for brain
structures.
Double-labeling studies performed in P7 showed that
KAT I is localized in M€uller cell endfeet at P7 in the
chicken retina. This is in agreement with earlier data
which suggest that KAT I is preferentially expressed in
M€uller cell endfeet in the adult rat retina (Rejdak et al.,
2001). However, the immunohistochemistry was per-
formed at only one time point. It is possible that the cell-
type expressing KAT I could change as the retina
develops. In the rat hippocampus, KAT I immunore-
activity was observed mainly in glial cells (Du et al.,
1992), while in the striatum it was found in both glial
cells and neurons (Roberts et al., 1992). Predominantly
neuronal localization of KAT I was observed in the
spinal cord (Kapoor et al., 1997).
5. Conclusion
KAT I is present in the avascular chicken retina
during ontogeny and is localized in M€uller cell endfeet.
Since KAT I enzymatic activity is high in late embryonic
stages it is conceivable that it plays a neuromodulatory
role in the chicken retina during the late phase of em-
bryogenesis.
Acknowledgements
The study was supported by Fort€une Grant 994 of
the Medical Faculty of the University T€ubingen and the
European Union under the Marie Curie Individual
Fellowship to Dr. med. Robert Rejdak (QLK2-CT-
2002-51562).
References
Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri,
M., & Moroni, F. (2001). Presynaptic kynurenate-sensitive recep-
tors inhibit glutamate release. European Journal of Neuroscience,
13, 2141–2147.
Ceresoli-Borroni, G., & Schwarcz, R. (2001). Neonatal asphyxia in
rats: acute eﬀects on cerebral kynurenine metabolism. Pediatric
Research, 50, 231–235.
Csillik, A. E., Okuno, E., Csillik, B., Knyihar, E., & Vecsei, L. (2002).
Expression of kynurenine aminotransferase in the subplate of the
rat and its possible role in the regulation of programmed cell death.
Cerebral Cortex, 12, 1193–1201.
Du, F., Schmidt, W., Okuno, E., Kido, R., Kohler, C., & Schwarcz, R.
(1992). Localization of kynurenine aminotransferase immunoreac-
tivity in the rat hippocampus. Journal of Comparitive Neurology,
321, 477–487.
Gramsbergen, J. B., Schmidt, W., Turski, W. A., & Schwarcz, R.
(1992). Age-related changes in kynurenic acid production in rat
brain. Brain Research, 588, 1–5.
Grunder, T., Kohler, K., & Guenther, E. (2000). Distribution and
developmental regulation of AMPA receptor subunit proteins in
rat retina. Investigative Ophthalmology and Visual Science, 41,
3600–3606.
Grunder, T., Kohler, K., Kaletta, A., & Guenther, E. (2000). The
distribution and developmental regulation of NMDA receptor
subunit proteins in the outer and inner retina of the rat. Journal of
Neurobiology, 44, 333–342.
Guidetti, P., Okuno, E., & Schwarcz, R. (1997). Characterization of
rat brain kynurenine aminotransferases I and II. Journal of
Neuroscience Research, 50, 457–465.
Haberecht, M. F., & Redburn, D. A. (1996). High levels of
extracellular glutamate are present in retina during neonatal
development. Neurochemistry Research, 21, 285–291.
Fig. 2. Localization of KAT I in the chicken retina at P7: (A) positive immunoreaction of KAT I antibody in radial sections of the chicken retina;
triangles mark the brightly stained band along the retina-vitreous border and an arrow shows an unstained cell body in the innermost row of the INL;
(B) positive immunoreaction of glutamine synthetase antibody (triangles and arrow mark the same structures as in A) and (C) immunostaining in A
(red) and B (green) was merged; yellow color indicates the co-localization of both antibodies in the endfeet and ascending processes of M€uller cells.
ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar ¼ 20
lm.
1516 R. Rejdak et al. / Vision Research 43 (2003) 1513–1517
Hilmas, C., Pereira, E. F., Alkondon, M., Rassoulpour, A., Schwarcz,
R., & Albuquerque, E. X. (2001). The brain metabolite kynurenic
acid inhibits alpha7 nicotinic receptor activity and increases non-
alpha7 nicotinic receptor expression: physiopathological implica-
tions. Journal of Neuroscience, 21, 7463–7473.
Kapoor, R., Okuno, E., Kido, R., & Kapoor, V. (1997). Immuno-
localization of kynurenine aminotransferase (KAT) in the rat
medulla and spinal cord. Neuroreport, 8, 3619–3623.
Kessler, M., Terramani, T., Lynch, G., & Baudry, M. (1989). A glycine
site associated with N -methyl-D-aspartic acid receptors: character-
ization and identiﬁcation of a new class of antagonists. Journal of
Neurochemistry, 52, 1319–1328.
Knyihar-Csillik, E., Okuno, E., & Vecsei, L. (1999). Eﬀects of in vivo
sodium azide administration on the immunohistochemical local-
ization of kynurenine aminotransferase in the rat brain. Neuro-
science, 94, 269–277.
Komuro, H., & Rakic, P. (1993). Modulation of neuronal migration
by NMDA receptors. Science, 260, 95–97.
Moroni, F., Russi, P., Lombardi, G., Beni, M., & Carla, V. (1988).
Presence of kynurenic acid in the mammalian brain. Journal of
Neurochemistry, 51, 177–180.
Okuno, E., Du, F., Ishikawa, T., Tsujimoto, M., Nakamura, M.,
Schwarcz, R., & Kido, R. (1990). Puriﬁcation and characterization
of kynurenine-pyruvate aminotransferase from rat kidney and
brain. Brain Research, 534, 37–44.
Okuno, E., Nakamura, M., & Schwarcz, R. (1991). Two kynurenine
aminotransferases in human brain. Brain Research, 542, 307–312.
Perkins, M. N., & Stone, T. W. (1982). An iontophoretic investigation
of the actions of convulsant kynurenines and their interaction with
the endogenous excitant quinolinic acid. Brain Research, 247, 184–
187.
Rejdak, R., Zarnowski, T., Turski, W. A., Okuno, E., Kocki, T.,
Zagorski, Z., Kohler, K., Guenther, E., & Zrenner, E. (2001).
Presence of kynurenic acid and kynurenine aminotransferases in
the inner retina. Neuroreport, 12, 3675–3678.
Rejdak, R., Zarnowski, T., Turski, W. A., Kocki, T., Zagorski, Z.,
Guenther, E., Kohler, K., & Zrenner, E. (2002). Changes of
kynurenic acid content in the rat and chicken retina during
ontogeny. Graefes Archives for Clinical and Experimental Ophthal-
mology, 240, 687–691.
Roberts, R. C., Du, F., McCarthy, K. E., Okuno, E., & Schwarcz, R.
(1992). Immunocytochemical localization of kynurenine amino-
transferase in the rat striatum: a light and electron microscopic
study. Journal of Comparitive Neurology, 326, 82–90.
Schwarcz, R., Poeggeler, B., Rassoulpour, A., Ceresoli-Borroni, G., &
Hodgkins, P. S. (1998). Regulation of kynurenic acid levels in the
developing rat brain. Amino Acids, 14, 243–249.
Somohano, F., Roberts, P. J., & Lopez-Colome, A. M. (1988).
Maturational changes in retinal excitatory amino acid receptors.
Brain Research, 470, 59–67.
Speciale, C., Wu, H. Q., Gramsbergen, J. B., Turski, W. A.,
Ungerstedt, U., & Schwarcz, R. (1990). Determination of extra-
cellular kynurenic acid in the striatum of unanesthetized rats: eﬀect
of aminooxyacetic acid. Neuroscience Letters, 116, 198–203.
Stazka, J., Luchowski, P., Wielosz, M., Kleinrok, Z., & Urbanska, E.
M. (2002). Endothelium-dependent production and liberation of
kynurenic acid by rat aortic rings exposed to L-kynurenine.
European Journal of Pharmacology, 448, 133–137.
Turski, W. A., Gramsbergen, J. B., Traitler, H., & Schwarcz, R. (1989).
Rat brain slices produce and liberate kynurenic acid upon exposure
to L-kynurenine. Journal of Neurochemistry, 52, 1629–1636.
Turski, W. A., Nakamura, M., Todd, W. P., Carpenter, B. K.,
Whetsell, W. O., Jr., & Schwarcz, R. (1988). Identiﬁcation and
quantiﬁcation of kynurenic acid in human brain tissue. Brain
Research, 454, 164–169.
Turski, W. A., & Schwarcz, R. (1988). On the disposition of
intrahippocampally injected kynurenic acid in the rat. Experimental
Brain Research, 71, 563–567.
Urbanska, E. M., Chmielewski, M., Kocki, T., & Turski, W. A. (2000).
Formation of endogenous glutamatergic receptors antagonist
kynurenic acid–diﬀerences between cortical and spinal cord slices.
Brain Research, 878, 210–212.
Wolburg, H., Liebner, S., Reichenbach, A., & Gerhardt, H. (1999).
The pecten oculi of the chicken: a model system for vascular
diﬀerentiation and barrier maturation. International Review of
Cytology, 187, 111–159.
R. Rejdak et al. / Vision Research 43 (2003) 1513–1517 1517
